secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxcyte, Inc. (PCVX)
CIK:        0001649094
Form:       8-K
Filed at:   2023-11-06T23:59:59+00:00
Accession:  0000950170-23-059386
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxcyte Q3 net loss $92.7M; FDA clears VAX-31 IND; VAX-24 Phase 3 agreed
------------------------------------------------------------------------

- Net loss $92.7M vs $57.9M YoY; cash $1.43B (up from $957.9M Dec 2022).
- Completed End-of-Phase 2 FDA meeting for VAX-24 adult Phase 3; topline data expected 2025.
- FDA cleared VAX-31 adult IND; Phase 1/2 starts Q4 2023, topline data H2 2024.
- Expanded Lonza collaboration for commercial manufacturing of VAX-24 and VAX-31.
- VAX-24 infant Phase 2 advanced to Stage 2 with comparator Prevnar 20.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649094/000095017023059386/0000950170-23-059386-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649094/000095017023059386/pcvx-20231106.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-059386

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer